{"id":38926,"date":"2017-07-18T00:00:00","date_gmt":"2017-07-17T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/"},"modified":"2020-11-16T16:21:58","modified_gmt":"2020-11-16T15:21:58","slug":"la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/","title":{"rendered":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros"},"content":{"rendered":"<p>La operaci\u00f3n se lanza tras el cierre, a finales del a\u00f1o pasado, de una ronda de financiaci\u00f3n de 2 millones de euros, y del reciente acuerdo de licencia con la americana Corino Therapeutics para el desarrollo cl\u00ednico y comercializaci\u00f3n del f\u00e1rmaco SOM0226 contra el amiloidosis por transtiretina (ATTR), que obtuvo resultados muy prometedores en el estudio de Fase 2a realizado en el Hospital Vall de Hebr\u00f3n de Barcelona.\u00a0<\/p>\n<p>SOM Biotech destinar\u00e1 los recursos obtenidos a realizar los ensayos cl\u00ednicos de sus programas m\u00e1s avanzados: SOM3355 para la enfermedad de Huntington (el segundo producto de la compa\u00f1\u00eda que llega a fase cl\u00ednica), y SOM1201 para la adrenoleucodistrofia (ALD), una enfermedad gen\u00e9tica rara y neurodegenerativa, ligada al cromosoma X. Ambos compuestos son f\u00e1rmacos reposicionados, es decir, previamente aprobados para otra indicaci\u00f3n, por lo que el riesgo y el nivel de inversi\u00f3n para desarrollar nuevas aplicaciones terap\u00e9uticas son mucho m\u00e1s reducidos.<\/p>\n<p>\u201cDespu\u00e9s de 7 a\u00f1os y muchos esfuerzos, SOM entra en una agresiva fase de crecimiento internacional para convertirse en la compa\u00f1\u00eda de referencia a nivel mundial en el reposicionamento de f\u00e1rmacos. Hemos pasado la primera fase de concepto de negocio con la primera licencia y nos queda un crecimiento ordenado que aporte valor continuado a nuestros inversores de forma sostenida\u201d, explica Ra\u00fal Insa, CEO de SOM Biotech.\u00a0<\/p>\n<p>En total, desde su creaci\u00f3n en 2009, la compa\u00f1\u00eda ha levantado m\u00e1s de 5,3 millones de euros procedentes de capital p\u00fablico y privado.<\/p>\n<p>\u201cActualmente, SOM Biotech tiene un valor de compa\u00f1\u00eda te\u00f3rico superior a los 100M\u20ac avalado por expertos independientes, hecho que ya est\u00e1 permitiendo regresos de la inversi\u00f3n muy importantes para algunos accionistas. Ahora, el gran reto es que los tres productos l\u00edderes lleguen al mercado en los pr\u00f3ximos 5 a\u00f1os y que otros nuevos entren en desarrollo cl\u00ednico para conseguir un valor de compa\u00f1\u00eda m\u00ednimo de 500M\u20ac\u201d, afirma el Dr. Insa.<\/p>\n<p>\n<span style=\"color:#000000\"><strong><span style=\"font-size:16px\">Nueva sede en los Estados Unidos<\/span><\/strong><\/span><\/p>\n<p>Esta inyecci\u00f3n de capital tambi\u00e9n permitir\u00e1 a la biofarmac\u00e9utica dar un fuerte impulso a su expansi\u00f3n en el mercado norteamericano, ya que el lanzamiento de la ronda Serie A coincide con la apertura en los Estados Unidos de su primera sede internacional.\u00a0<\/p>\n<p>La oficina, ubicada en Cambridge (Massachusetts), est\u00e1 dirigida por Michael Greenberg, un reconocido experto en desarrollo de negocio del sector salud con m\u00e1s de 20 a\u00f1os de experiencia en la negociaci\u00f3n de alianzas internacionales y direcci\u00f3n de compa\u00f1\u00edas biofarmac\u00e9uticas l\u00edderes en los Estados Unidos, Reino Unido, Espa\u00f1a, Alemania, Israel, Taiw\u00e1n, Jap\u00f3n, India y China.<\/p>\n<p>Inicialmente, su actividad se focalizar\u00e1 en la promoci\u00f3n de proyectos de licencia y codesarrollo en el campo del reposicionamento de f\u00e1rmacos para enfermedades minoritarias neurol\u00f3gicas en Norteam\u00e9rica y Asia.<\/p>\n<p>\u00a0<\/p>\n<p>\u25ba <a href=\"http:\/\/www.pcb.ub.edu\/portal\/ca\/noticies\/-\/noticia\/not_som-biotech-llicencia-el-seu-farmac-som0226-per-al-tractament-de-la-amiloidosis-per-transtiretina-a-l-americana-corino-therapeutics?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">N<\/a><a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/noticies\/-\/noticia\/not_som-biotech-llicencia-el-seu-farmac-som0226-per-al-tractament-de-la-amiloidosis-per-transtiretina-a-l-americana-corino-therapeutics?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">oticia relacionada [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_003948&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">SOM Biotech <\/a>\u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 acaba de abrir una ronda Serie A por importe de 10M\u20ac.\u00a0Desde su fundaci\u00f3n\u00a0en el Parc Cient\u00edfic de Barcelona en 2009, la biofarmac\u00e9utica ha levantado m\u00e1s de 5.3M\u20ac procedentes de capital p\u00fablico y privado y ha depositado 8 patentes de nueva indicaci\u00f3n m\u00e9dica o formulaci\u00f3n.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":26181,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-38926","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"SOM Biotech \u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 acaba de abrir una ronda Serie A por importe de 10M\u20ac.\u00a0Desde su fundaci\u00f3n\u00a0en el Parc Cient\u00edfic de Barcelona en 2009, la biofarmac\u00e9utica ha levantado m\u00e1s de 5.3M\u20ac procedentes de capital p\u00fablico y privado y ha depositado 8 patentes de nueva indicaci\u00f3n m\u00e9dica o formulaci\u00f3n. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-17T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:21:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros\",\"datePublished\":\"2017-07-17T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:21:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/\"},\"wordCount\":503,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/16049222035fa92b5b76c47.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/\",\"name\":\"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/16049222035fa92b5b76c47.jpeg\",\"datePublished\":\"2017-07-17T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:21:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/16049222035fa92b5b76c47.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/16049222035fa92b5b76c47.jpeg\",\"width\":800,\"height\":458},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/","og_locale":"es_ES","og_type":"article","og_title":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona","og_description":"SOM Biotech \u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 acaba de abrir una ronda Serie A por importe de 10M\u20ac.\u00a0Desde su fundaci\u00f3n\u00a0en el Parc Cient\u00edfic de Barcelona en 2009, la biofarmac\u00e9utica ha levantado m\u00e1s de 5.3M\u20ac procedentes de capital p\u00fablico y privado y ha depositado 8 patentes de nueva indicaci\u00f3n m\u00e9dica o formulaci\u00f3n. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2017-07-17T23:00:00+00:00","article_modified_time":"2020-11-16T15:21:58+00:00","og_image":[{"width":800,"height":458,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros","datePublished":"2017-07-17T23:00:00+00:00","dateModified":"2020-11-16T15:21:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/"},"wordCount":503,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/","url":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/","name":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg","datePublished":"2017-07-17T23:00:00+00:00","dateModified":"2020-11-16T15:21:58+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/07\/16049222035fa92b5b76c47.jpeg","width":800,"height":458},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/la-biofarmaceutica-som-biotech-abre-una-ronda-serie-a-de-10-millones-de-euros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"La biofarmac\u00e9utica SOM Biotech abre una ronda Serie A de 10 millones de euros"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=38926"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38926\/revisions"}],"predecessor-version":[{"id":45028,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/38926\/revisions\/45028"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/26181"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=38926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=38926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=38926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}